mRNA cancer vaccines: Advances, trends and challenges

mRNA cancer vaccines: Advances, trends and challenges

Patients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are re...

Full description

Bibliographic Details
Main Authors:	Qing He, Hua Gao, Dejiang Tan, Heng Zhang, Jun-zhi Wang
Format:	Article
Language:	English
Published:	Elsevier 2022-07-01
Series:	Acta Pharmaceutica Sinica B
Subjects:	mRNA Cancer vaccine Tumor-associated antigens Neoantigens mRNA delivery vectors Adjuvants
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383522001198

Similar Items

Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
by: Yuan Yuan, et al.
Published: (2023-01-01)

Advances in mRNA-Based Cancer Vaccines
by: Ling Ni
Published: (2023-10-01)

mRNA vaccine designs for optimal adjuvanticity and delivery
by: Yuki Mochida, et al.
Published: (2024-12-01)

Advancing mRNA technologies for therapies and vaccines: An African context
by: Dylan Kairuz, et al.
Published: (2022-10-01)

Efficient mRNA Delivery with mRNA Lipoplexes Prepared Using a Modified Ethanol Injection Method
by: Min Tang, et al.
Published: (2023-04-01)

Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
by: Yusi Wang, et al.
Published: (2022-02-01)

Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases
by: Lu Yang, et al.
Published: (2022-07-01)

mRNA therapeutics: New vaccination and beyond
by: Huan-Huan Wei, et al.
Published: (2023-09-01)

The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
by: Reese Jalal Ladak, et al.
Published: (2022-05-01)

mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
by: Shuqin Xu, et al.
Published: (2020-09-01)

mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
by: Ziyang Xu, et al.
Published: (2023-03-01)

mRNA vaccines in the prevention and treatment of diseases
by: Yangzhuo Gu, et al.
Published: (2022-09-01)

mRNA—From COVID-19 Treatment to Cancer Immunotherapy
by: Werner Krause
Published: (2023-01-01)

PEGylation of mRNA by Hybridization of Complementary PEG-RNA Oligonucleotides Stabilizes mRNA without Using Cationic Materials
by: Naoto Yoshinaga, et al.
Published: (2021-05-01)

Progress and challenges of mRNA vaccines
by: Liangru Lin, et al.
Published: (2023-01-01)

mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications
by: Yu-Shiuan Wang, et al.
Published: (2023-10-01)

mRNA‐based chimeric antigen receptor T cell therapy: Basic principles, recent advances and future directions
by: Kaiting Xiao, et al.
Published: (2024-01-01)

Development and Delivery Systems of mRNA Vaccines
by: Yongjun Liang, et al.
Published: (2021-07-01)

Modified mRNA Formulation and Stability for Cardiac and Skeletal Muscle Delivery
by: Magdalena M. Żak, et al.
Published: (2023-08-01)

Corrigendum: Development and Delivery Systems of mRNA Vaccines
by: Yongjun Liang, et al.
Published: (2021-09-01)

Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development
by: Zhi-liang Wang, et al.
Published: (2022-10-01)

mRNA vaccine: a potential therapeutic strategy
by: Yang Wang, et al.
Published: (2021-02-01)

The Pivotal Role of Chemical Modifications in mRNA Therapeutics
by: Albert Liu, et al.
Published: (2022-07-01)

Advances in mRNA Vaccines for Infectious Diseases
by: Cuiling Zhang, et al.
Published: (2019-03-01)

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
by: Chiranjib Chakraborty, et al.
Published: (2021-07-01)

Capillary electrophoresis methods for determining the IVT mRNA critical quality attributes of size and purity
by: Denise A Warzak, et al.
Published: (2023-10-01)

An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo
by: Md. Motiar Rahman, et al.
Published: (2021-03-01)

Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
by: Berta Segura-Collar, et al.
Published: (2023-05-01)

Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines
by: Iman M. Alfagih, et al.
Published: (2020-12-01)

Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines
by: Feng Lin, et al.
Published: (2023-11-01)

Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities
by: De‐feng Li, et al.
Published: (2023-05-01)

Post-RNA (mRNA) Vaccination Myocarditis: CMR Features
by: Karuna M. Das, et al.
Published: (2022-04-01)

How mRNA therapeutics are entering the monoclonal antibody field
by: Lien Van Hoecke, et al.
Published: (2019-02-01)

Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration
by: Xueliang Yu, et al.
Published: (2021-11-01)

Ionizable Lipid Nanoparticles for mRNA Delivery
by: Xuefeng Tang, et al.
Published: (2023-08-01)

A Comprehensive Review of mRNA Vaccines
by: Vrinda Gote, et al.
Published: (2023-01-01)

Have mRNA vaccines sentenced DNA vaccines to death?
by: Alberto Cagigi, et al.
Published: (2023-12-01)

The Delivery of mRNA Vaccines for Therapeutics
by: Nitika, et al.
Published: (2022-08-01)

Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
by: Magdalena M. Żak, et al.
Published: (2021-10-01)

Gelatin Nanoparticles for Complexation and Enhanced Cellular Delivery of mRNA
by: Lea Andrée, et al.
Published: (2022-09-01)